ReviewAnnals of gastroenterological surgery2020
Application of liquid biopsy for surgical management of pancreatic cancer.
Review in Annals of gastroenterological surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- To Evaluate Whether Pretreatment CA19-9 and DUPAN-2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer.Annals of gastroenterological surgery · 2026Article
- Diagnostic methods for pancreatic cancer and their clinical applications (Review).Oncology letters · 2025Review
- Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.Scientific reports · 2024Article
- Identifying the Trends of Urinary microRNAs within Extracellular Vesicles for Esophageal Cancer.Cancers · 2024Article
- Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid.Oncology letters · 2024Article
- Clinical Application of Liquid Biopsy in Pancreatic Cancer: A Narrative Review.International journal of molecular sciences · 2024Review
- Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement.Annals of gastroenterological surgery · 2024Article
- Review
- Anticancer Peptides Derived from Aldolase A and Induced Tumor-Suppressing Cells Inhibit Pancreatic Ductal Adenocarcinoma Cells.Pharmaceutics · 2023Article
- Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics-A Review.Digestive diseases and sciences · 2023Review
- Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer.International journal of molecular sciences · 2023Review
- Tumor microenvironment interactions with cancer stem cells in pancreatic ductal adenocarcinoma.Advances in cancer research · 2023Review
- Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?Cancers · 2021Review
- Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma.Frontiers in medicine · 2021Review
- Exosomes in osteosarcoma research and preclinical practice.American journal of translational research · 2021Review
- Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer.International journal of molecular sciences · 2020Review
- Application of liquid biopsy for surgical management of pancreatic cancer.Annals of gastroenterological surgery · 2020Review
- A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial.Therapeutic advances in medical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Although drug development over the past decade has gradually improved the prognosis of PDAC, the prognosis remains extremely poor. The predominant determinant of a poor prognosis is that patients are already at the advanced stage when they are diagnosed. Therefore, it is essential to detect early-stage PDAC to ensure a good prognosis. However, in general, being asymptomatic at the early stage makes the detection of early-stage PDAC very difficult. Recently, much attention has been focused on the utility of a liquid biopsy as a biomarker. Theoretically, early-stage tumors can be detected even under asymptomatic conditions. A number of studies on liquid biopsies have been reported so far. Several biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCS), and exosomes, are used in liquid biopsies, with the potential to be applied to the clinical setting. Each biomarker is reported to have different utilities, such as the detection of early-stage disease, the differential diagnosis of PDAC from other types of pancreatic tumors, the prediction of the prognosis or risk of recurrence, and monitoring the treatment response. In this review, we focus on ctDNA, CTCS, and exosomes as representative liquid biopsy biomarkers and describe the specific functions of each biomarker in the treatment of PDAC. Furthermore, we discuss the application of liquid biopsies, especially for the surgical management of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.